Loading [Contrib]/a11y/accessibility-menu.js

This website uses cookies

We use cookies to enhance your experience and support COUNTER Metrics for transparent reporting of readership statistics. Cookie data is not sold to third parties or used for marketing purposes.

Skip to main content
Journal of Intellectual Property
  • Menu
  • Articles
    • General
    • All
  • For Authors
  • Editorial Board
  • About
  • Issues
  • Blog
  • search
  • X (formerly Twitter) (opens in a new tab)
  • Facebook (opens in a new tab)
  • LinkedIn (opens in a new tab)
  • RSS feed (opens a modal with a link to feed)

RSS Feed

Enter the URL below into your favorite RSS reader.

http://localhost:38318/feed
P-ISSN 2575-3819
E-ISSN 2575-3827
General
Vol. 22, Issue 1, 2014January 01, 2014 EDT

Trade Secret Rising: Protecting Equivalency Test Research and Development Investments After Momenta v. Amphastar

Hannah-Alise Rogers,
patentHatch-Waxman ActFood and Drug AdministrationFDAsafe harbortrade secretFOIAAbbreviated New Drug ApplicationANDAUniform Trade Secrets ActUTSAdrug manufacturersgeneric manufacturerspharmaceuticalbioequivalency test; Momenta v. Amphastar
Journal of Intellectual Property
Hannah-Alise Rogers, Trade Secret Rising: Protecting Equivalency Test Research and Development Investments After Momenta v. Amphastar, 22 Journal of Intellectual Property 209 (2014).

View more stats

Powered by Scholastica, the modern academic journal management system